Sensus Healthcare Reports First Quarter 2024 Financial Results With Revenues up More than Three-fold
BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three months ended March 31, 2024.
- Revenues for the first quarter of 2024 were $10.7 million, compared with $3.4 million for the first quarter of 2023, an increase of $7.3 million, or 215%.
- Other income of $0.2 million for the first quarter of 2024 was mostly related to interest income, and was unchanged from the prior-year quarter.
- Adjusted EBITDA for the first quarter of 2024 was $3.0 million, compared with negative $2.7 million for the first quarter of 2023.
- Non-GAAP financial measures are not formally defined by GAAP, and other entities may use calculation methods that differ from those used by Sensus Healthcare.